Webinar: Liquid Biopsy Landscape

Liquid Biopsy Landscape: CtDNA in Lung Cancer Research

ctDNA analysis holds significant promise in lung cancer management, offering opportunities for early detection, personalized treatment selection, and real-time monitoring of treatment response.
Despite its promise, several challenges and limitations remain in the clinical implementation of ctDNA analysis for lung cancer. These include issues related to sensitivity and specificity, detection of low-frequency mutations, standardization of methodologies, and cost-effectiveness. Addressing these challenges will be crucial for further advancing the utility of ctDNA analysis in routine clinical practice.

Liquid Biopsy Landscape Webinar

In this webinar, we delved into the intricacies of analyzing ctDNA and other LBx biomarkers and explored strategies to overcome existing challenges, paving the way for its widespread adoption in clinical settings. Watch the recording now.

View Webinar

Our Experts

Dasha Kaloujskaia

House Speaker

Research Analyst

Beacon

Frank Plowden

Moderator

Account Manager

Beacon

You May Also Be Interested In…

WCLC 2026 Conference Intelligence Report

Access Report

Oncology H1 2026 Landscape Review

Access Review

ASCO 2026 Highlights: Where Oncology is Moving Next

View Infographic

View All

What is Beacon?

Beacon is the essential intelligence platform for R&D decision-makers working in pharma and biotech, offering unique technology and drug datasets for complex therapeutics and disease areas.

Our market-defining proprietary ontologies, manual data curation, and accurate and comprehensive life science data, provide our customers with unparalleled visibility of the drug, trial and commercial landscape.

This is why 24 of the top 25 pharmaceutical companies trust Beacon to power their critical pipeline, competitive, and commercial decisions.

We’d welcome the opportunity to show you how Beacon can transform your data strategy. Book your personalized demonstration today!

Request Demonstration